Ianosi Gabriel, Ianosi Simona, Calbureanu-Popescu Madalina Xenia, Tutunaru Cristina, Calina Daniela, Neagoe Daniela
Department of Surgery, Medical Center Dr. Ianosi, University of Medicine and Pharmacy of Craiova, 200000 Craiova, Romania.
Department of Dermatology, Medical Center Dr. Ianosi, University of Medicine and Pharmacy of Craiova, 200000 Craiova, Romania.
Exp Ther Med. 2019 Feb;17(2):1106-1112. doi: 10.3892/etm.2018.6985. Epub 2018 Nov 16.
Telangiectasias and reticular veins of the lower extremities are common lesions. Sclerotherapy is considered the gold standard for treatment. The aim of our prospective randomized study was to compare the efficacy and safety of hypertonic 20% saline/2% lignocaine (HS) versus polidocanol 0.5% (POL) versus long-pulsed neodymium:ytrium aluminium garnet (Nd:YAG) laser (LAS) treatments of leg telangiectasias in women, using each patient as her own control. We included in this study 285 women with primary leg telangiectasias and reticular veins (CEAP) in order to be treated with sclerotherapy or laser. One leg was treated with either LAS, POL or HS. The other leg received, randomly, one other of these treatments. At the end there were 190 legs treated with each method. There were two sessions at 8-week interval. Assessment of vessel clearing and complications was conducted 2 months after each session using before and after photographs of the leg vessels using a six-point scale from 0 (no change) to 5 (100% cleared). For telangiectasias under 1 mm diameter LAS was better (RR=9.72, P<0.0001) than HS and also POL was better (RR=2.70, P=0.003); for telangiectasias over 1 mm diameter LAS and POL were better too (RR=2.70, P=0.003) respectively (RR=1.44, P=0.00756). For telangiectasias under 1 mm LAS treatment is clearly superior to POL treatment. For telangiectasias over 1 mm the hazard regression model showed a hazard ratio of 3.97 (P=0.047) for LAS and 4.96 (P=0.486) for POL vs. HS treatment. In conclusion, telangiectasias and reticular veins of the lower extremities can be successfully treated with Nd:YAG laser or sclerotherapy. Nd:YAG laser is recommended in treating small telangiectasias (under 1 mm diameter) while sclerotherapy with polidocanol is more efficient as long as telangiectasias diameter is growing.
下肢毛细血管扩张和网状静脉是常见的病变。硬化疗法被认为是治疗的金标准。我们这项前瞻性随机研究的目的是,以每位患者自身作为对照,比较20%高渗盐水/2%利多卡因(HS)、0.5%聚多卡醇(POL)和长脉冲钕:钇铝石榴石(Nd:YAG)激光(LAS)治疗女性腿部毛细血管扩张的疗效和安全性。我们纳入了285例患有原发性腿部毛细血管扩张和网状静脉(CEAP)的女性,以便接受硬化疗法或激光治疗。一条腿用LAS、POL或HS进行治疗。另一条腿随机接受另外一种治疗。最后,每种方法治疗了190条腿。每隔8周进行两个疗程。在每个疗程后2个月,使用腿部血管治疗前后的照片,采用从0(无变化)到5(100%清除)的六点量表对血管清除情况和并发症进行评估。对于直径小于1mm的毛细血管扩张,LAS优于HS(RR = 9.72,P < 0.0001),POL也优于HS(RR = 2.70,P = 0.003);对于直径大于1mm的毛细血管扩张,LAS和POL也分别更优(RR = 2.70,P = 0.003)(RR = 1.44,P = 0.00756)。对于直径小于1mm的毛细血管扩张,LAS治疗明显优于POL治疗。对于直径大于1mm的毛细血管扩张,风险回归模型显示,与HS治疗相比,LAS的风险比为3.97(P = 0.047),POL的风险比为4.96(P = 0.486)。总之,下肢毛细血管扩张和网状静脉可以用Nd:YAG激光或硬化疗法成功治疗。建议用Nd:YAG激光治疗小的毛细血管扩张(直径小于1mm),而随着毛细血管扩张直径增大,聚多卡醇硬化疗法更有效。